The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of QingSong Health Corporation 轻松健康集团 (Incorporated in the Cayman Islands with lim ...

Core Insights - WELL Health Technologies Corp. reported strong interim consolidated financial results for the quarter ended September 30, 2025, indicating positive growth and performance [1] Financial Performance - The company experienced significant growth in its financial metrics, reflecting a successful quarter driven by strategic initiatives [1] - Specific financial figures and percentage changes were not detailed in the provided text, but the overall performance was characterized as excellent [1] Strategic Focus - WELL Health Technologies is focused on leveraging technology to enhance health outcomes for healthcare practitioners and patients globally, emphasizing its commitment to digital healthcare solutions [1]

Core Points - WELL Health Technologies Corp. will announce its Fiscal Third Quarter 2025 financial results on November 6, 2025, before market opens [1] - A conference call will be held on the same day at 1:00 PM ET to discuss the results, hosted by the CEO and CFO [2][3] Company Overview - WELL Health is a digital healthcare company focused on improving health outcomes through technology, serving over 42,000 healthcare providers across the US and Canada [4] - The company operates the largest owned and operated healthcare ecosystem in Canada, with more than 220 clinics providing various healthcare services [4] - WELL's solutions target specialized markets in the US, including gastrointestinal health, women's health, primary care, and mental health [4]

Core Insights - Hydreight Technologies Inc. has reported significant growth, processing over 295,000 VSDHOne product orders from July to September 2025, indicating a robust expansion in its nurse network and a strong financial position with approximately CA$18.7 million in cash [1][6][9]. Company Performance - The company ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada for revenue growth from 2021 to 2024, and previously ranked 56 on Deloitte's 2024 Technology Fast 500™ in the U.S., highlighting its leadership in modernizing healthcare delivery through technology [3][6]. - Hydreight operates one of the largest compliant telehealth and medical networks in the U.S., connecting healthcare providers, pharmacies, and patients through its VSDHOne platform across all 50 states [4][13]. Recent Highlights - The company saw a 49% year-over-year increase in new nurse sign-ups, with 198 new sign-ups between July and September 2025 compared to 133 in the same period last year, and a total of 593 sign-ups in the first nine months of 2025, up from 364 in 2024 [9]. - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, reflecting sustained growth across multiple wellness verticals [9]. Financial Position - Hydreight enhanced its liquidity with an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing its cash position to approximately CA$18.7 million as of October 22, 2025 [9][12]. - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value while scaling its telehealth infrastructure nationally [12]. Strategic Initiatives - The company is actively integrating 503A/503B pharmacy partners to improve capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9]. - Hydreight is expanding its GLP-1 program and direct-to-consumer wellness offerings, with ongoing national rollout initiatives [10][9]. Industry Recognition - Hydreight has been recognized as a Top 50 TSX Venture Exchange Company for 2024 and selected as a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8].

Core Insights - Hydreight Technologies Inc. has reported significant growth in product orders and nurse network expansion, with over 295,000 VSDHOne product orders processed between July and September 2025, indicating a strong demand for its services [1][9] - The company has a robust cash position of approximately CA$18.7 million, positioning it well for future growth initiatives [6][9] - Hydreight has received multiple recognitions for its rapid growth and innovation, including being ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada [3][8] Company Performance - The company processed ~295,000 VSDHOne product orders from July to September 2025, reflecting broad growth across various wellness verticals [9] - Nurse network expansion saw 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year, and a total of 593 sign-ups in the first nine months of 2025, up ~63% from 2024 [9] - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, indicating sustained growth and broader adoption [9] Financial Position - Hydreight's liquidity was enhanced by an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing cash reserves to approximately CA$18.7 million as of October 22, 2025 [9] - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value [12] Strategic Developments - Hydreight is actively integrating 503A/503B pharmacy partners to improve capacity and fulfillment speed, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9] - The company is rolling out Dr. Franklin Joseph's GLP-1 program nationally to meet increasing patient demand [10] - Hydreight is evaluating potential mergers and acquisitions of profitable multi-state wellness and digital health operators to scale nationally [9] Industry Recognition - Hydreight was recognized as a Top 50 TSX Venture Exchange Company for 2024 and was a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8] - The company has been acknowledged for its leadership in modernizing healthcare delivery through technology and compliance [3]

Core Insights - Becton, Dickinson and Company (BDX) has launched the AI-enabled BD Incada Connected Care Platform and the next-generation BD Pyxis Pro Automated Medication Dispensing Solution, marking a significant advancement in its Connected Care strategy [1][7] - The BD Incada Platform, built on Amazon Web Services (AWS), integrates data from millions of smart devices to enhance medication availability and streamline workflows, reinforcing BD's leadership in digital healthcare innovation [2][4] Company Developments - The BD Incada Platform aims to transform device data into actionable intelligence, improving efficiency and patient safety through real-time analytics and natural language insights [8] - The BD Pyxis Pro Solution modernizes medication dispensing with enhanced storage, automation, and security features, addressing space constraints in hospitals while minimizing medication retrieval errors [9] Market Performance - Following the announcement of the new products, BDX shares remained flat, with a year-to-date decline of 15.8%, contrasting with the industry’s growth of 2.8% and the S&P 500's gain of 14.4% [3] - BDX currently holds a market capitalization of $52.2 billion [6] Strategic Positioning - The integration of AI, cloud connectivity, and real-time analytics positions BDX for long-term growth in the expanding digital healthcare ecosystem, driving recurring software and service revenues [4][10] - The convergence of hardware and AI analytics enhances BD's competitive advantage, opening opportunities in cloud services and subscription-based models, which could lead to steady margin expansion and long-term shareholder value creation [10]

Core Insights - Mobile-health Network Solutions (MNDR) has secured a strategic investment of US$900,000 from Indopacific Health Investment Corporation to enhance its growth strategy and market entry in Indonesia [1][3] - The investment follows an earlier subscription of US$150,000 in May 2025, bringing Indopacific's total investment in MNDR to US$1.05 million [3] - The funds will primarily be allocated for the acquisition of Lifepack, a digital pharmacy platform in Indonesia, and to support broader market initiatives across Southeast Asia [3][4] Investment Details - The share purchase was executed under a Securities Purchase Agreement dated September 10, 2025, with shares priced at US$1.80 each [2] - The transaction includes customary closing conditions and lock-up provisions in accordance with Nasdaq requirements [2] Company Overview - Mobile-health Network Solutions is an AI-powered digital health platform based in Singapore, with operations across Southeast Asia and plans to expand into the US [5] - The company focuses on providing telemedicine, AI-driven health tools, and virtual clinic infrastructure to enhance healthcare accessibility [5]

Financial Data and Key Metrics Changes - Stryker reported crossing $20 billion in sales in February 2023 and is now moving towards $30 billion with another year of double-digit organic sales growth in February 2024 [27] Business Line Data and Key Metrics Changes - The company completed seven tuck-in acquisitions in 2024, strengthening its category leadership across various business areas [28] - Stryker has two FDA-approved AI solutions in the market and a robust pipeline of digital solutions being launched or planned for the future [34] Market Data and Key Metrics Changes - Stryker impacted over 150 million patients in 2024, indicating a strong market presence and commitment to healthcare [29] Company Strategy and Development Direction - The company emphasizes innovation as a key driver for consistent high growth and has maintained its mission and values for over eleven years [27][28] - Stryker is focusing on advanced digital healthcare to improve operational and clinical outcomes, leveraging data and new technologies like AI [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong performance for 2025 and beyond, highlighting the company's position for continued growth [37] - The leadership team acknowledged the importance of employee efforts and customer collaboration in driving innovation and service excellence [36] Other Important Information - The company announced leadership transitions, including the appointment of a new Chief Communications Officer and a new Chief Financial Officer [12] Q&A Session Summary Question: How does the compensation committee use the compensation actually paid total compensation figures in its calculation of the CEO target total compensation award for the upcoming year? - The CEO explained that realized pay is based on stock performance over time, and the compensation committee uses an outside adviser to help set compensation, emphasizing that most of the CEO's pay is at risk [21][22][23] Question: How is Stryker leveraging data and new technologies like AI to drive product innovations and improve patient outcomes? - The CEO stated that Stryker has two FDA-approved AI solutions and a strong pipeline of digital solutions, which are crucial for future product offerings [34]

Core Insights - ReShape Lifesciences has entered an exclusive distribution agreement with Motion Informatics to import and distribute neuromuscular rehabilitation devices in the U.S. market [1][2] - The flagship product, Stimel-03, integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback [2] - This partnership aims to enhance patient outcomes and expand the market reach of both companies in the neuromuscular rehabilitation sector [2][3] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® System and investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system [4] - Motion Informatics focuses on next-generation neuromuscular rehabilitation, utilizing AI-driven neuroinformatics and augmented reality to create adaptive therapeutic platforms [3] - The collaboration positions both companies at the forefront of the neuromuscular rehabilitation market, aiming for global expansion and improved clinical care [2][3]

Core Insights - WELL Health Technologies Corp. is set to release its Fiscal Fourth Quarter and Year End 2024 financial results on April 14, 2025, after market close [1] - A conference call to discuss the results will take place on April 15, 2025, at 1:00 PM ET, hosted by the CEO and CFO [1][2] Company Overview - WELL Health Technologies Corp. focuses on leveraging technology to improve health outcomes for healthcare practitioners and patients globally [1] - The company provides a comprehensive healthcare and digital platform that includes front and back-office management software applications, supporting over 41,000 healthcare providers in the US and Canada [2] - WELL operates the largest owned and operated healthcare ecosystem in Canada, with more than 200 clinics offering primary care, specialized care, and diagnostic services [2] - In the US, WELL's solutions target specialized markets such as gastrointestinal health, women's health, primary care, and mental health [2]